JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 96 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.12 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,260,000 | -20.2% | 254,590 | 0.0% | 0.04% | -21.7% |
| Q1 2019 | $1,578,000 | +82.6% | 254,590 | -0.7% | 0.05% | +31.4% |
| Q4 2018 | $864,000 | -68.8% | 256,473 | -39.7% | 0.04% | -58.8% |
| Q3 2018 | $2,765,000 | -70.3% | 425,415 | -65.0% | 0.08% | -73.1% |
| Q2 2018 | $9,304,000 | -64.8% | 1,214,593 | +2.7% | 0.32% | -69.0% |
| Q1 2018 | $26,426,000 | +111.4% | 1,182,393 | +20.6% | 1.02% | +87.8% |
| Q4 2017 | $12,500,000 | -16.0% | 980,393 | +2.6% | 0.54% | -26.0% |
| Q3 2017 | $14,888,000 | -6.8% | 955,598 | -16.1% | 0.73% | -24.5% |
| Q2 2017 | $15,971,000 | -29.1% | 1,138,370 | +2.2% | 0.97% | -33.5% |
| Q1 2017 | $22,523,000 | – | 1,114,160 | – | 1.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |